BUPROPION HYDROCHLORIDE | A076143 | APOTEX INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Senores Pharmaceuticals, Inc. FDA-2026-P-0748 · 9 docket documents Senores Pharmaceuticals, Inc. filed this suitability petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA declare Bupropion Hydrochloride Tablets 150 mg suitable for submission in an ANDA, as the proposed strength differs from the reference listed d | Suitability | 2026-01-26 | GrantedNo FDA response document on docket | Senores Pharmaceuticals, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1151
per ea
Lowest NADAC/Unit
$0.0942
per ea
Brand NDCs
0
Generic NDCs
10
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 68001030900BUPROPION HCL 100 MG TABLET | $0.1151 | EA | Generic | — | 2026-08-19 |
| 60687035101BUPROPION HCL 100 MG TABLET | $0.1151 | EA | Generic | — | 2026-08-19 |
| 60505015701BUPROPION HCL 100 MG TABLET | $0.1151 | EA | Generic | — | 2026-08-19 |
| 50268014315BUPROPION HCL 100 MG TABLET | $0.1151 | EA | Generic | — | 2026-08-19 |
| 00904663661BUPROPION HCL 100 MG TABLET | $0.1151 | EA | Generic | — | 2026-08-19 |
| 68001030800BUPROPION HCL 75 MG TABLET | $0.0942 | EA | Generic | — | 2026-08-19 |
Showing 6 of 10 NDCs.
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.